Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 153.45 INR
Change Today +3.10 / 2.06%
Volume 140.1K
JOL On Other Exchanges
Natl India
As of 7:05 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

jubilant life sciences ltd (JOL) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/13/14 - 222.00
52 Week Low
12/17/14 - 115.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

jubilant life sciences ltd (JOL) Related Businessweek News

No Related Businessweek News Found

jubilant life sciences ltd (JOL) Details

Jubilant Life Sciences Limited, an integrated pharmaceutical and life sciences company, manufactures and supplies pharmaceutical and life sciences products and services worldwide. The company provides active pharmaceutical ingredients (APIs) for cardiovascular system (CVS) and central nervous system (CNS), as well as anti-infective and anti-ulcerants. Its APIs include solid dosage formulations for CVS, CNS, and anti-allergy categories; radiopharmaceuticals for the diagnosis, treatment, and monitoring of diseases; and allergy therapy products, including allergenic extracts and mixes, and skin test devices. The company also offers life sciences ingredients, such as pyridine and picoline; fine chemicals; crop science chemicals; nutrition products, including niacinamide, niacin (vitamin B3), and choline chloride; animal nutrition products in the category of vitamin and mineral premixes, betaine, acidifiers, toxin binders, growth promoters, and emulsifiers; acetyl products, which include acetic acid, monochloro acetic acid, acetic anhydride, ethyl acetate, and sodium mono chlor acetate; and specialty gases, such as liquid carbon dioxide and ethylene oxide mixtures. In addition, it provides contract manufacturing services in manufacturing sterile injectables, and solid and semi solid dosage forms; drug discovery services in bioinformatics, chemoinformatics, and crystallography structure directed molecular design and information technology; pre clinical services, such as medicinal chemistry, analytical chemistry, custom synthesis, library design, and clinical development and market launch services; and conducts integrated drug discovery and development programs on oncology, metabolic disorders, pain, and inflammation. The company was formerly known as Jubilant Organosys Limited and changed its name to Jubilant Life Sciences Limited in 2010. Jubilant Life Sciences Limited was incorporated in 1978 and is based in Noida, India.

6,100 Employees
Last Reported Date: 02/3/15
Founded in 1978

jubilant life sciences ltd (JOL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jubilant life sciences ltd (JOL) Key Developments

Jubilant Life Sciences Ltd. Announces Board Changes

Jubilant Life Sciences Ltd. announced that consequent to appointment of Mr. Shyam S. Bhartia as Chairman and Managing Director of Jubilant Pharma Limited, Singapore, he has resigned from the position of Managing Director of the company effective from March 25, 2015. In view of the above, Mr. Shyam S. Bhartia shall be Non-executive Chairman and Director of the company.

Jubilant Life Sciences Receives ANDA Approval for Montelukast

Jubilant Life Sciences Ltd. has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Montelukast Sodium Chewable Tablets, 4 mg and 5 mg, the generic version of Singulair Chewable Tablets® (of Merck), which is used for the treatment of asthma and to relieve symptoms of seasonal allergies. The total market size for Montelukast Tablets as per IMS is $83 Million per annum. As on December 31, 2014, Jubilant Life Sciences had a total of 781 filings for formulations of which 333 have been approved in various regions globally. This includes 72 ANDAs filed in the US, of which 35 have been approved and 46 Dossier filings in Europe. So far, it received 10 ANDA approvals during Fiscal Year 2015.

Jubilant Life Sciences Ltd Receives Abbreviated New Drug Application Final Approval from US FDA for Irbesartan Tablets USP, 75 mg, 150 mg, and 300 mg and Cetirizine Hydrochloride Tablets (Chewable), 5 mg and 10 mg

Jubilant Life Sciences Ltd. has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Irbesartan Tablets USP, 75 mg, 150 mg, and 300 mg, Cetirizine Hydrochloride Tablets (Chewable), 5 mg and 10 mg. Irbesartan Tablets USP, 75 mg, 150 mg, and 300 mg is the generic version of Avapro® (of Sanofi-Aventis), which is used for treating hypertension and nephropathy in type II diabetic patients. The total market size for Irbesartan Tablets as per IMS is approximately $50 million per annum. Cetirizine Hydrochloride Tablets (Chewable), 5 mg and 10 mg is the generic version of Zyrtec Chewable Tablets® (of Mcneil), used as an anti-histamine for the treatment of allergies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JOL:IN 153.45 INR +3.10

JOL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dishman Pharmaceuticals & Chemicals Ltd 159.20 INR +3.65
Glenmark Pharmaceuticals Ltd 906.60 INR +16.30
Piramal Enterprises Ltd 944.00 INR +5.90
Shasun Pharmaceuticals Ltd 325.95 INR +12.60
Torrent Pharmaceuticals Ltd 1,172 INR -30.25
View Industry Companies

Industry Analysis


Industry Average

Valuation JOL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.4x
Price/Book 0.9x
Price/Cash Flow 8.3x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JUBILANT LIFE SCIENCES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at